VANCOUVER, BC--(Marketwire - March 10, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) today announced that the company’s novel drug candidates to treat the parasitic disease leishmaniasis have demonstrated good safety profiles in their first in vivo toxicity tests in mice. The toxicity screening studies were conducted at Makerere University in Uganda, which is also conducting initial efficacy and toxicity screening for Upstream’s candidates to treat trypanosomiasis, or African sleeping sickness. An estimated 350 million people in 88 countries are at risk of contracting leishmaniasis each year, and the incidence of infection is on the rise.
